A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy

Trial Profile

A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Daratumumab (Primary) ; Bortezomib; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms Alcyone
  • Sponsors Genmab; Janssen Biotech; Janssen Research & Development
  • Most Recent Events

    • 24 Aug 2017 According to a Genmab media release, data are expected to be submitted for presentation at an upcoming medical conference and for publication in a peer-reviewed journal.
    • 24 Aug 2017 According to a Genmab media release, IDMC, after conducting a pre-planned analysis of the interim data, recommended to unblind data.
    • 24 Aug 2017 Primary endpoint (Progression-free Survival (PFS) has been met, according to a Genmab media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top